PCI Biotech Holding ASA

Equities

PCIB

NO0010405640

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 30/05/2024 BST			5-day change	1st Jan Change
2.05 ^NOK	+1.23%		+22.90%	-2.15%

02-14	PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing	CI

PCI Biotech Holding ASA Appoints Ronny Skuggedal as Chief Financial Officer, Effective November 1, 2013

September 19, 2013 at 03:11 pm

Ronny Skuggedal has been appointed as new CFO in PCI Biotech Holding ASA. Ronny Skuggedal is currently Director in PWC where he has been an auditor and advisor since 2001. Ronny Skuggedal will assume his position as CFO no later than November 1, 2013.

Latest news about PCI Biotech Holding ASA

PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Pci Biotech Initiates Field Testing of Its Proprietary Technology for Gene Therapy Manufacturing	13/10/23	CI
PCI Biotech Holding ASA Announces European Patent Office Intends to Grant A New Patent Covering Delivery of mRNA	07/09/23	CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/08/23	CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2022	16/02/23	CI
PCI Biotech Holding ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/02/23	CI
PCI Biotech Holding ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23/11/22	CI
PCI Biotech Holding ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	31/08/22	CI
Transcript : PCI Biotech Holding ASA, Q2 2022 Earnings Call, Aug 31, 2022	31/08/22
PCI Biotech Announces PH II Clinical Trail Update	18/08/22	CI
PCI Biotech Holding ASA Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22	CI
Transcript : PCI Biotech Holding ASA, Q1 2022 Earnings Call, May 11, 2022	11/05/22
PCI Biotech CEO to Step Down to Join Exact Therapeutics	28/03/22	MT
PCI Biotech Holding ASA Announces Resignation on Per Walday as Chief Executive Officer	28/03/22	CI
PCI Biotech Holding ASA(OB:PCIB) dropped from S&P Global BMI Index	21/03/22	CI
PCI Biotech Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2021	18/02/22	CI
PCI Biotech Holding ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	18/02/22	CI
Transcript : PCI Biotech Holding ASA, Q4 2021 Earnings Call, Feb 18, 2022	18/02/22
Transcript : PCI Biotech Holding ASA - Special Call	25/01/22
PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies	25/01/22	MT
PCI Biotech Holding ASA Provides Update on the RELEASE Trial	24/01/22	CI
PCI Biotech Announces Publication of Preclinical Tuberculosis Results	11/01/22	CI
Norway's PCI Biotech, South Korea-based MDimune Join Preclinical Research Partnership	05/01/22	MT
PCI Biotech and MDimune Announce Research Collaboration Agreement	05/01/22	CI

Chart PCI Biotech Holding ASA

Duration

Period

More charts

Company Profile

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotechâs product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PCI BIOTECH HOLDING ASA	-2.15%	7.15M
VERTEX PHARMACEUTICALS INCORPORATED	+7.77%	114B
REGENERON PHARMACEUTICALS, INC.	+9.06%	104B
ARGENX SE	-1.63%	22.57B
BIONTECH SE	-11.88%	22.5B
GENMAB A/S	-10.39%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-14.33%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+2.53%	13.55B
SAREPTA THERAPEUTICS, INC.	+27.42%	10.99B

Bio Therapeutic Drugs